Intrinsic bioscience moves closer to formulating amino acids as a treatment for cystic fibrosis
Vidyasagar and his team, which included researchers from UF and Integral Biosciences, demonstrated that Nuvara’s VS-009 formula may benefit patients with cystic fibrosis class I mutations as well as class II and III. The therapy could be used alone or in combination with other therapies to improve chloride secretion.
Stephen J. Gattoexecutive chairman of Nuvara Therapeutics, congratulated Astrid Grosche and the rest of Dr. Vidyasagar’s team for their continued commitment to finding innovative ways to assess respiratory epithelial function.
“I want to thank Astrid, Dr. Vidyasagar and the rest of her team for their tireless commitment to solving cystic fibrosis class I mutations, a mutation that can affect up to 18% of the CF population,” said Stephen J. Gatto.
“These two abstracts show that manipulation of ion channels is possible in the respiratory epithelium using tailored formulations of amino acids,” Gatto continued. “Ion channel dysfunction is central to many diseases, such as cystic fibrosis and diseases in which there is increased mucus production, including asthma and COPD. These approaches/treatments will allow us to modulate the influx of ions and water into the airways at the cellular level with minimal side effects.
“There’s still work to be done, but the opportunity is really exciting and could represent a breakthrough in the management of channelopathies and related diseases,” Gatto said.
Vidyasagar also presented a poster on a tool his lab has developed to better measure intestinal peristalsis and the interactions of intraluminal pressure, muscle contraction, and fluid volume changes.
“These two abstracts are unique in that they show the ability to modulate epithelial transmembrane proteins (eTMPs) with a selective amino SAA (RxAA) formulation,” said Dr. William Demann, Chief Medical Advisor of Nuvara Therapeutics. “This opens the door to effective, non-toxic therapy at the basic cellular level, regardless of etiology.”
Dr Denman continued: “Future treatments can now be determined and tailored to the individual channel and disease – true personalized medicine. Further work is needed, but this may enable treatment alternatives at the cellular level across disease spectra with minimal side effects.
Entrinsic Bioscience is a UF startup located at UF Innovate | Accelerate at Sid Martin Biotech by Alachua. The company develops all-natural, glucose-free formulations for clinical hydration, gut health and wellness, allergy and skincare.
Nuvara Therapeutics has licensed EBS technologies for all therapeutic applications.
Company details :
Joe DelRegno, [email protected]
About Intrinsic Bioscience
Entrinsic Bioscience (EBS) is a pioneering life science company that combines its proprietary IP platform and discovery engine to deliver next-generation patented therapeutic compositions, functional ingredients and product innovations designed to deliver multiple consumer health and welfare benefits. Using proprietary biomapping and electrophysiology techniques, the EBS platform harnesses the body’s natural processes to restore, protect and enhance health and well-being.
About Nuvara Therapeutics
Nuvara Therapeutics is a next-generation clinical-stage therapeutics company targeting the dysregulation of epithelial transmembrane protein (ETP) that causes serious gastrointestinal and respiratory diseases. The company is the first to discover that novel combinations of prescription amino acids (RxAAs™) can modulate ETPs via cell signaling to treat disease. With its highly customizable platform, Nuvara Therapeutics is leading the way in tackling serious disease states with high unmet need, including potentially breakthrough treatments for CF – Class 1 mutation, ARDS, asthma , COPD, diarrheal disease and constipation.
Nuvara technology comes from a NASA of 40 million dollars | BARDA grant to study the effects of gastrointestinal toxicity during long-duration space travel. The company was created to leverage technology licensed from Entrinsic Bioscience to focus on the development of new drugs.
About UF Innovate:
UF Innovate is the umbrella organization bringing together the four entities that drive the innovation ecosystem at UF. Based at one of the nation’s leading research institutes, UF Innovate includes Tech Licensing, Ventures, Pathways and an Accelerate program, which includes two business incubators, The Hub and Sid Martin Biotech. Together, these organizations move research discoveries from the lab to the marketplace. UF Innovate connects innovators with entrepreneurs, investors, and industry, incubates startups and growth companies, and fosters a resilient economy, all with the goal of making the world a better place. In 2020, the George W. Bush Institute and Opus Faveo ranked the University of Florida #1 in innovation impact, naming it the nation’s most productive large university for mobilizing research funding into new businesses, new jobs, and new ideas.
SOURCENuvara Therapeutics; Intrinsic Biosciences